Phase II trial of enfortumab vedotin in patients with previously treated gastric and esophageal cancers

EV demonstrated antitumor activity in patients with predominantly heavily pretreated la/m GEA or ESCC. The predefined threshold for promising antitumor activity was met in patients with ESCC but not in those with GEA. Safety was manageable and consistent with previous reports.

Authors

Institutions

Publication Details

Journal
ESMO Open
Published
2025-10-23
DOI
https://doi.org/10.1016/j.esmoop.2025.105806
Citations
1
Primary Topic
Gastric Cancer Management and Outcomes
Type
article
Field-Weighted Citation Impact
1.52

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Phase II trial of enfortumab vedotin in patients with previously treated gastric and esophageal cancers

Changting Meng, Yuko Kuboki, H. Hara, Soichiro Kondo et al.
1 citations
ESMO Open
Gastric Cancer Management and Outcomes
1.52
article

Phase II trial of enfortumab vedotin in patients with previously treated gastric and esophageal cancers

Changting Meng, Yuko Kuboki, H. Hara, Soichiro Kondo, Mary F. Mulcahy, Satoshi Hamauchi, Jason Kaplan, Steven B. Maron, Ning Jin, Joaquina Baranda, Sheng Liu, Marcin Woźniak, Ryan Dillon, Seema Rao Gorla, F P Gardner, Seiichiro Mitani, Srinivasu Poondru, Keisho Chìn, Fadi S. Braiteh
article en
1 citations

Abstract

EV demonstrated antitumor activity in patients with predominantly heavily pretreated la/m GEA or ESCC. The predefined threshold for promising antitumor activity was met in patients with ESCC but not in those with GEA. Safety was manageable and consistent with previous reports.

ESMO OpenVol. 10(11)
Northwestern University (US), Memorial Sloan Kettering Cancer Center (US), Pfizer (United States) (US), Shizuoka Cancer Center (JP), Saitama Cancer Center (JP), University of Kansas Medical Center (US), Aichi Cancer Center (JP), National Cancer Center Hospital East (JP), Tokyo National Hospital (JP), Comprehensive Cancer Centers of Nevada (US), Astellas Pharma (United States) (US), Japanese Foundation For Cancer Research (JP), The Ohio State University (US), Kindai University (JP)
Pfizer, Seagen, Astellas Pharma, Astellas Foundation for Research on Metabolic Disorders
Openalex Percentile: Top 13%
Gastric Cancer Management and Outcomes
1.52
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.